Candel Therapeutics (CADL) Stock: Buy, Sell, or Hold?
CADL - Candel Therapeutics, Inc. Common Stock
$10.55
-0.79 (-6.93%)
▼
5d:
-18.7%
30d:
-1.26%
90d:
+29.23%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When CADL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CADL is down 18.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CADL is down 18.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CADL is currently trading at $10.54, which is considered oversold relative to its 30-day fair value range of $10.87 to $13.19. From a valuation perspective, the stock is trading at a discount (Forward PE: -16.9) compared to its historical average (40.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CADL is showing support break momentum. Immediate support is located at $9.86, while resistance sits at $13.80. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: CADL scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+99.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CADL is showing support break momentum. Immediate support is located at $9.86, while resistance sits at $13.80. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: CADL scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+99.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.87 -
$13.19
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.9%)
- BULLISH: Trading 99.1% below Wall St target ($21.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.87 -
$13.19
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$9.86
Resistance Level
$13.80
Current Trend
Support Break
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.87
Wall Street Target
$21.00
(+99.1%)
PE vs Historical
-16.9 vs 40.5
CHEAP
Share & Embed Analysis
Last updated: September 12, 2026 3:10 PM ET
Data refreshes hourly during market hours. Next update: 4:10 PM
Data refreshes hourly during market hours. Next update: 4:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CADL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 50 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$289 | 59 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
